top of page
Search

Lung Cancer: Small Cell vs Non-Small Cell

TL;DR

For MRCP Part 1, distinguishing Resp: Lung Cancer: Small Cell vs. Non-Small Cell is essential. Small cell lung cancer (SCLC) is aggressive, centrally located, and managed primarily with chemotherapy and radiotherapy, while non-small cell lung cancer (NSCLC) is more diverse, staged using TNM, and often treated surgically if detected early. Key exam areas include paraneoplastic syndromes, staging systems, and management pathways. Expect comparison-style MCQs.


Why this matters

Lung cancer is one of the most frequently tested respiratory topics in MRCP Part 1, reflecting its global clinical significance. The exam often assesses your ability to differentiate small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC) using clinical clues, investigations, and management decisions.

A strong grasp of this distinction helps you answer both straightforward recall questions and nuanced clinical scenarios.

👉 Begin with the MRCP Part 1 overview to structure your preparation effectively.


Core sections

1. Classification and histology

Lung cancer is broadly divided into:

  • Small Cell Lung Cancer (SCLC)

    • Neuroendocrine origin

    • Small, round, blue cells

    • High mitotic activity

    • Strongly associated with smoking

  • Non-Small Cell Lung Cancer (NSCLC) (~85%)

    • Adenocarcinoma: peripheral, most common, seen in non-smokers

    • Squamous cell carcinoma: central, cavitating

    • Large cell carcinoma: poorly differentiated

2. Key differences at a glance

Feature

SCLC

NSCLC

Growth rate

Rapid

Slower

Location

Central

Peripheral (adeno), central (squamous)

Metastasis

Early and widespread

Later

Staging

Limited vs extensive

TNM staging

Treatment

Chemotherapy ± radiotherapy

Surgery ± chemo/radiotherapy

Paraneoplastic syndromes

Common

Less common

3. Staging systems (high-yield exam point)

  • SCLC staging

    • Limited disease: confined to one hemithorax

    • Extensive disease: beyond this

  • NSCLC staging

    • TNM (Tumour, Node, Metastasis) system

    • Determines surgical eligibility

💡 Exam tip: If a question uses limited vs extensive, it is referring to SCLC.

4. Clinical presentation patterns

Common symptoms:

  • Persistent cough

  • Haemoptysis

  • Weight loss

  • Dyspnoea

SCLC clues:

  • Rapid onset and progression

  • Early metastasis (brain, liver, bone)

NSCLC clues:

  • Peripheral lesions → often asymptomatic early

  • Adenocarcinoma common in non-smokers

5. Paraneoplastic syndromes (very testable)

  • SCLC

    • SIADH → hyponatraemia

    • Ectopic ACTH → Cushing’s syndrome

    • Lambert-Eaton myasthenic syndrome

  • NSCLC

    • Squamous cell carcinoma → hypercalcaemia (PTHrP)

    • Adenocarcinoma → hypertrophic osteoarthropathy

6. Management principles

  • SCLC

    • Rarely surgical

    • Chemotherapy (platinum-based regimens)

    • Radiotherapy

    • Prophylactic cranial irradiation (PCI)

  • NSCLC

    • Early stage → surgical resection (lobectomy)

    • Advanced stage → chemotherapy/immunotherapy

    • Targeted therapy (e.g. EGFR, ALK mutations)

👉 Reinforce management concepts with Free MRCP MCQs.

7. Prognosis differences

  • SCLC

    • Poor prognosis

    • Rapid progression

  • NSCLC

    • Variable prognosis

    • Better outcomes if detected early

8. High-yield summary (memorise for MRCP Part 1)

  1. SCLC = aggressive, central, chemo-based treatment

  2. NSCLC = heterogeneous, surgery possible

  3. SCLC uses limited/extensive staging

  4. NSCLC uses TNM staging

  5. SCLC → SIADH, ACTH production

  6. Squamous cell → hypercalcaemia

  7. Adenocarcinoma → peripheral, common in non-smokers

  8. PCI is specific to SCLC

  9. Surgery rarely used in SCLC

  10. Targeted therapy applies to NSCLC


Practical examples / mini-cases

MCQ Example

A 65-year-old smoker presents with confusion and lethargy. Blood tests show sodium of 120 mmol/L. Imaging reveals a central lung mass.

What is the most likely diagnosis?

A. AdenocarcinomaB. Squamous cell carcinomaC. Small cell lung cancerD. Large cell carcinoma

✅ Answer: C. Small cell lung cancer

Explanation: Hyponatraemia due to SIADH is strongly associated with SCLC. The presence of a central mass and rapid systemic symptoms further supports this diagnosis.


Medical student preparing for MRCP Part 1 studying lung cancer notes

Common pitfalls (5 bullets)

  • Assuming adenocarcinoma is always smoking-related

  • Forgetting that SCLC is rarely treated surgically

  • Mixing up staging systems (SCLC vs TNM)

  • Missing paraneoplastic clues in MCQs

  • Overlooking incidental or early-stage NSCLC presentations


FAQs

1. Which lung cancer is most aggressive?

SCLC is the most aggressive form, with rapid growth and early metastasis.

2. Which lung cancer is most common overall?

Adenocarcinoma (a subtype of NSCLC) is the most common globally.

3. Why is SCLC not treated with surgery?

It is usually disseminated at diagnosis, making local surgical treatment ineffective.

4. What causes hypercalcaemia in lung cancer?

Squamous cell carcinoma produces PTH-related peptide (PTHrP), leading to hypercalcaemia.

5. What staging system is used for NSCLC?

NSCLC is staged using the TNM classification system.


Ready to start?

Lung cancer distinctions are a recurring theme in MRCP exams. Strengthen your exam performance with structured revision and practice:

👉 Suggested next topic: Interstitial Lung Diseases for MRCP Part 1


Sources

 
 
 

Comments

bottom of page